BBA 2026 Winner Profile: New Market Entrant – Lifebit

British Business Awards

 

Written by Sterling Content


 

Biotechnology and health-data company Lifebit Biotech Ltd. has scooped the New Market Entrant British Business Award at the BCCJ’s red carpet gala in early November.

 

The UK-based company, which builds federated Trusted Research Environments and AI analytics platforms to analyse sensitive genomic, clinical and real-world health data without moving it, was recognised for having “entered Japan with ambition, strategic clarity and tangible commitment, creating early value while building strong potential for sustained success in the market.” 

 

Kent Zaitlik, director of APAC for Lifebit, said the win was a complete surprise, but reflects that the work of Lifebit in Japan is “really taking shape and making an impact.”

 

 

Solid track record

 

Lifebit is working with Geonomics England, a UK-government-owned organisation that delivers whole genome sequencing diagnostics through the NHS, to develop a next-generation research environment for improving public health. The company provides Genomics England with a Trusted Research Environment comprising 60 petabytes of data and more than 1,200 researchers. In July 2026, it won a 5-year, £19.5 million contract to build the platform’s successor.

 

Genomic data is used in areas such as precision medicine (to tailor treatments based on a patient’s genetic profile) and disease diagnosis (to estimate disease predisposition).

 

As advances in genomic research increasingly depend on the ability to analyse large, complex datasets, Lifebit’s Trusted Research Environments play a key role in ensuring data is both accessible and protected, supporting more personalised, data-driven healthcare for patients. According to Genomics England, Lifebit’s research environment “represents a significant investment in the future of genomic research.”

 

 

Entering the Japan market

 

Lifebit has partnered with Tokyo-based Mitsui Knowledge Industry to bring its Trusted Research Environments to Japan. The aim is to support Japan towards its national goal of sharing genomic and clinical data across institutions by fiscal year 2029. Until now, privacy law and institutional governance have kept such data in separate places, but Lifebit has enabled the use of sensitive health data on a national level, without the need to ever move data across borders or institutions.

 

Through Lifebit’s strategic alliance with Mitsui Knowledge Industry, the platform has been adapted to Japanese security and governance requirements and deployed at the University of Tokyo’s Institute of Medical Science.

Stakeholder engagement

 

With Mitsui Knowledge Industry, Lifebit delivers Japanese-language training, documentation and support while building Japan’s skills in federated analysis and data standardisation to the OMOP Common Data Model. This open, international standard harmonises disparate healthcare data, such as electronic health records, into a single structure with shared vocabulary, enabling cross-border, privacy-preserving observational research and real-world evidence generation without moving raw patient data between institutions.

 

Japanese partners have also visited Genomics England and the NIHR (National Institute for Health and Care Research) Biomedical Research Centre: Cambridge, and Lifebit has advised on the technical and security requirements for Japan’s platforms.

 

Lifebit is also shaping Japan’s platforms, so they are compatible with those of the UK and Singapore, allowing Japanese researchers to gain a route into international studies while maintaining the security of patient data. The approach is expected to provide the basis for a national research collaboration on cancer and rare diseases across populations that no country could study alone. 

 

This year, the company also co-hosted a Trusted Research Environment conference in Tokyo with the University of Tokyo, Genomics England and Mitsui, and spoke at the UK–Japan Policy Dialogue on Critical Technologies.

 

 

Further expansion

 

Alongside its growth in Japan, Lifebit has become a delivery partner for the Department of Health in Abu Dhabi, United Arab Emirates, bringing together nearly 950,000 genomes and more than two billion clinical and claims records. The company’s platform will give approved researchers from academia, healthcare providers and pharmaceutical and biotechnology companies governed access to genomic and health data.

 

Meanwhile, Lifebit continues its long-term plan to support Japan’s targets for multi-site sharing of genetic data. It envisions that each new institution joins as its own secure environment, on the cloud of its choice, so the network grows without moving data or rebuilding.

 

“Japan has so much knowledge and insight … I foresee that Japan will be a huge contributor to the betterment of our technology: they’re going to be asking a lot of really good questions and testing everything again and again,” said Zaitlik. “Then the platform is going to become better and better, not just for Japan but for everyone.”